Cover
Vol. 3 No. 2 (2013)

Published: December 31, 2013

Pages: 11-14

Research Article

Evaluation of Cancer Antigens (CA125&CA153-) in some Iraqi women with polycystic ovarian syndrome

Nawal Khairy Hussain AL-Ani 1 Zainab Faeiq Rzaij 2
1High Inst. Infert. Diag. &Art. Al-Nahrain University Baghdad/Iraq
2AL Karamma Teaching Hospital
History
  • Received: September 1, 2013
  • Available Online: December 1, 2013

Abstract

Background: Polycystic ovary syndrome (PCOS) is the most common cause of hyperandrogenism anovulatory infertility; it affects 510-% of females in the reproductive age. PCOS is a risk disease; it has an association with gynecological malignancy. Objectives: To determine whether Cancer Antigen 125 (CA125) and Cancer Antigen 153-(CA153-) levels are increased in PCOS and possibility of CA125 and CA153- to be used as a diagnostic marker of PCOS. Methods: Seventyfemales with PCOS diagnosed depending on threecriteria: Menstrualhistoryofoligomenorrhea ultrasound examinations revealed polycystic ovaries and biochemical hyperandrogenism. Twenty normal fertile females serve as control group. Blood samples were obtained from all individuals from 2nd-4th day of menstrual cycle to measure levels of FSH, LH and testosterone.Second blood samples were collected from the same patients during late follicular phase to measure CA153- and CA125( by ELISA). Results: Females with PCOS and controls differed significantly(p< 0.05) in total serum testosterone (p). Females with PCOS and controls have highly significant difference (p < 0.001) in LH mean level (7.881.83+ vs 3.900.73+) respectivelyand, highly significant difference (p < 0.001) in LH/FSH ratio and BMI parameters. No significant differences (p > 0.05) were found in FSH, CA125 and CA153- between PCOS patients and the controls.There were positive correlation between testosterone and CA125.Negative correlation between testosterone and CA153- serum values. Conclusion: There were no changes in the serum levels of CA125andCA153- in PCOS patient at the age of reproduction and those cancer antigens could not be used as diagnostic markers for polycystic ovarian syndrome.

Keywords

References

  1. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome Lancet. 2007:370: 685697-.
  2. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod.2004; 19:41-47.
  3. Jedel E,. Waern M, Gustafson.D, Landen M, Eriksson.E,. Holm G L.et al. Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Hum Reprod. 2010: 25:450-456.
  4. Li Y, Yu Ng EH, Stener-Victorin E,Hou L, Wu T, Han F, et al. Polycystic ovary syndrome is associated with negatively variable impacts on domains of health-related quality of life: evidence froma meta analysis. Fertil Steril. 2011: 96:452-458.
  5. ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81: 19-25.
  6. Chamlian DL, Taylor HB. Endometrial hyperplasia in young women. Obstet Gynecol. 1970;36:659-66.
  7. Cheung AP. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstet Gynecol. 2001;98:32531.
  8. Gadducci A, Gargini A, Palla E, Fanucchi A, Genazzani AR. Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol Endocrinol. 2005:20: 200-8.
  9. Soran A, Ibott EO, Zborowski JV, Wilson JW. The prevalence of benign breast disease in women with polycystic ovary syndrome: a review of a 12 year follow-up. Int J Clin Pract. 2005; 59: 795-797.
  10. Norman R, Davies MJ, Lord J, Moran LJ. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab. 2002; 13: 251-257.
  11. Tchagang AB, Tewfik AH, DeRycke MS, Skubitz KM, Skubitz AP.Early detection of ovarian cancer using group biomarkers. Mol Cancer Ther. Jan 2008:7:2737-.
  12. Gallup DG& Talledo E. Management of the adnexal mass in the1990s. South Med J 1997:90:97281-.
  13. Tietz Wu A Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. 2006. pp 206-207.
  14. Clarke W. and Dufour D R. Contemporary Practice in Clinical Chemistry: AACC Press, Washington, DC. 2006. P р 247.
  15. Chan DW, Beveridge RA, Muss H, Fritsche HA, Hortobagyi G, Theriault R, et al. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage Il and stage III disease. J Clin Oncol. 1997: 15:2322-2328.
  16. Xita N& Tsatsoutis A. Fertile programming of PCOS byandrogen excess: Evidence from experimental, Clinical and genetic association studies. J Clin Endocrinol Metab. 2006:7.
  17. Chittenden B G, Fullerton G, Maheshwari A,Bhattacharya S.Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod. Biomed. Online. 2009; 19: 398-405.
  18. Fleming J, Beaugie C, Haviv I, Chenevix-Trench G, Tan OL.Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: Revisiting old hypotheses. Molecular and Cellular Endocrinology. 2006;247:4-21.
  19. Ahonen, MH, Zhuang, YH, Aine, R, Ylikomi, T, Tuohimaa, P.Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer. 2000; 86:40-6.
  20. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst.1998; 90:1774-86.
  21. Schildkraut JM, Schwingl PJ, Bastos E,Evanoff A, Hughes C. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol. 1996; 88:554-9.
  22. Murphy AA, Cropp CS, Smith BS, Burkman RT, Zacur HA. Effect of lowdose oral contraceptive on gonadotropins, androgens, and sex hormone binding globulin in nonhirsute women. Fertil Steril. 1990; 53:35-9.
  23. Adam Balen.PCOS and cancer, Human reproduction. 2001; 7:522525.
  24. Henderson BE, Casagrande JT, Pike MC, Mack T, Rosario I, Duke A. The epidemiology of endometrial cancer in a young women. Br.J.cancer. 1983:47:749-756.
  25. Eloowd JM, Cole P, Rothman KJ, Kaplan S.D. Epidmiology of endometrial cancer.J.Natl cancer Inst. 1977:59:1055-1060.
  26. Nicolini A,Anselmi L, Michelassi C, Carpi A.Prolonged survival by 'early salvage treatment of breast cancer patients: A retrospective 6-year study. Eur J Cancer. 1997: 76: 1106-1111.
  27. Ohuchi N, Sato S. Akimoto M Taira Y, Matoba N. Takahashi K, et al. Correlation between the immunohistochemical expression of DF3 antigen and serum CA 153- in breast cancer patients. Jpn J Surg. 1991; 21: 129137.
  28. Coulam, CB,Annegers JF and KranzJS. Chronic anovulation syndrome and associated neoplasia.Obestet.Gynecol. 1983;61,403-407.
  29. Gammon MD and ThompsonWD.() polycystic ovaries and the risk of breast cancer. Am.J.Epidmiol. 1991;134: 818-824.
  30. Gammon MD, Thompson WD. Polycystic ovaries and the risk ofbreast cancer. Am J Epidemiol. 1991;134:818-24.
  31. Anderson KE, Sellers TA, Chen PL,Rich SS. Hong CP. Folsom AR.Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in lowa. Cancer 1997:79:494-9.
  32. Gadducci A, Gargini A, Palla E,Fanucchi A, Genazzani AR.Polycystic ovary syndrome and gynecological cancers: is there alink? Gynecol Endocrinol.2005;20:200-8.